Clinical trial
Efficacy and Safety of Evinacumab in Patients With Homozygous Familial…
NCT03399786 · Regeneron Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT03399786 |
|---|---|
| Title | Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia |
| Official title | A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia |
| Lead sponsor | Regeneron Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Homozygous Familial Hypercholesterolemia |
| Intervention type | Drug |
| Interventions | evinacumab, Placebo |
| Enrollment | 65 |
| Start date | Jan 18, 2018 |
| Primary completion | Jun 10, 2019 |
| Completion | Mar 17, 2020 |
| First posted | Jan 16, 2018 |
| Last update posted | May 18, 2021 |
| Countries | Australia, Austria, Canada, France, Greece, Italy, Japan, Netherlands, South Africa, Ukraine, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: